Although the performance of UK-listed Big Pharmas is closely linked to changing US market dynamics, the impact on our UK smallcap life science universe will likely be more muted given its early-stage nature. Nevertheless, potential changes to drug pricing and healthcare provision resulting from the likely reversal of the Affordable Care Act (Obamacare) could impact a number of companies in our universe. We highlight Summit Therapeutics (Corporate), ReNeuron (Buy), Vectura (Buy), Verona Pharma (C ....
11 Nov 2016
N+1 Singer - Pharma & Biotech - Reflections on the UK sector post the US election
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Pharma & Biotech - Reflections on the UK sector post the US election
Futura Medical plc (FUM:LON), 36.0 | Craneware plc (CRW:LON), 2,265 | Advanced Medical Solutions Group plc (AMS:LON), 190 | ReNeuron Group plc (RENE:LON), 3.0 | Summit Therapeutics Inc (SMMT:NAS), 0 | Verona Pharma plc Sponsored ADR (VRNA:NAS), 0
- Published:
11 Nov 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
Although the performance of UK-listed Big Pharmas is closely linked to changing US market dynamics, the impact on our UK smallcap life science universe will likely be more muted given its early-stage nature. Nevertheless, potential changes to drug pricing and healthcare provision resulting from the likely reversal of the Affordable Care Act (Obamacare) could impact a number of companies in our universe. We highlight Summit Therapeutics (Corporate), ReNeuron (Buy), Vectura (Buy), Verona Pharma (C ....